The Cognitive Revolution• Feb 14, 2026• 2:25:42Panel

Approaching the AI Event Horizon? Part 2, w/ Abhi Mahajan, Helen Toner, Jeremie Harris, @8teAPi

From The Cognitive Revolution

Nathan Labenz(Host)•Avi Mahajan(Guest)•Helen Toner(Guest)•Jeremy Harris(Guest)•Prakash(Guest)

Executive Summary

The episode explores the intersection of AI with biology, automated R&D, and geopolitics, featuring experts on each topic.
In AI for drug discovery, the primary bottleneck is shifting from preclinical design to the high cost and low success rate of clinical trials, despite advances in predictive models.
Automated AI R&D is identified as a major source of strategic surprise, with experts lacking consensus on its timeline and impact, raising concerns about a widening gap between public and private capabilities.
The US AI industrial base faces critical geopolitical vulnerabilities, including dependence on TSMC for chips, Chinese components in the power grid, and a high concentration of Chinese nationals in top AI research roles.

12 quotes

Concerns Raised

The US AI industrial base is fundamentally insecure due to supply chain dependencies on Taiwan and China.
Automated AI R&D could lead to a rapid, uncontrollable intelligence explosion with significant strategic surprise.
A potential conflict over Taiwan could cripple global advanced semiconductor production.
The true bottlenecks in drug development (clinical trials) are not being effectively addressed by current AI applications.
Chinese-made components in the US power grid may contain trojan hardware for remote shutdowns.

Opportunities Identified

Leveraging AI to build 'human simulators' from rich tumor data to predict patient response to cancer treatments.
Acquiring promising and cost-effective preclinical drug assets from China's rapidly growing biotech industry.
AI-driven recursive self-improvement could dramatically accelerate scientific and technological progress.
New foundation models for biology could significantly improve predictions for protein-ligand binding and drug toxicity.

Key Themes

AI in Drug Discovery: Hype vs. Reality

While AI models like AlphaFold 3 and platforms like Noetic AI's show promise in predicting biological interactions and patient responses, the real-world impact is still limited. The discussion highlights that the primary bottleneck in drug development is not a lack of good preclinical assets but the immense challenge and cost of successful clinical trials, an area where AI has yet to prove transformative.

This provides a sober assessment for investors and researchers, suggesting that focus should shift from pure AI-driven design to solving the downstream challenges of clinical validation and translation.

Automated AI R&D and Strategic Surprise

Experts from frontier labs and policy circles struggle to forecast the speed and impact of AI systems that can automate and accelerate AI research itself. This uncertainty, highlighted by a CSET workshop, means that rapid, unexpected capability gains could occur within closed labs, challenging assumptions about manageable progress and creating a high risk of strategic surprise.

This uncertainty complicates AI governance and national security planning, as policymakers may be operating with an outdated understanding of state-of-the-art capabilities, necessitating robust transparency and auditing measures.

The Fragility of the US AI Supply Chain

The US AI ecosystem is critically dependent on foreign-controlled chokepoints. This includes an overwhelming reliance on Taiwan's TSMC for advanced chips, the presence of Chinese-made components (including potential trojans) in the US power grid, and the fact that a large percentage of top AI talent at US labs are Chinese nationals.

These vulnerabilities expose the US AI industry to severe disruption from geopolitical events, such as a conflict over Taiwan, or from targeted actions by strategic competitors, threatening the nation's technological leadership.

The Rise of China in Biotech and AI

China has evolved from a generics manufacturer to a major hub for CROs and now a source of innovative preclinical drug assets that are being acquired by Western biopharma. In AI, while perhaps scaling existing ideas, Chinese labs are producing powerful models like DeepSeek despite US export controls, indicating a resilient and rapidly advancing ecosystem.

This trend signals a shift in the global balance of power in both biotechnology and artificial intelligence, forcing Western companies and governments to reassess their competitive strategies and dependencies.

Identifying the Real Bottlenecks to Progress

Across domains, the conversation identifies non-obvious bottlenecks. In biology, it's the lack of verifiable ground truth for complex problems, not a lack of data. In US AI development, it's projected to be energy availability by late 2024. For Chinese AI labs, it's a lack of R&D compute due to high inference demand.

Understanding these true limiting factors is crucial for effective strategic investment and policymaking, as focusing on the wrong problem (e.g., only preclinical drug design) can lead to wasted resources and stalled progress.

Get started free

Topics

AI for Drug Discovery AI for Biology Preclinical Assets Clinical Trials Noetic AI Automated AI R&D Recursive Self-Improvement AI Safety Geopolitics US-China Relations AI Supply Chain TSMC Semiconductors National Security Energy Consumption

Processed Apr 3, 2026 yt-dlp + mlx-whisper + Gemini